The findings suggest that short peptides 17.1 and N1, which are fragments of innate immunity protein Tag7, can be used in the future as efficacious agents for the treatment or prevention of acute lung injury, e.g., in patients with COVID-19. The gene discussed is PGLYRP1; the disease is COVID-19.